Fig. 4 | Signal Transduction and Targeted Therapy

Fig. 4

From: Preventive and therapeutic benefits of nelfinavir in rhesus macaques and human beings infected with SARS-CoV-2

Fig. 4

Schedule of nelfinavir treatment and SARS-CoV-2 infection in rhesus macaques. To evaluate the prophylactic efficacy of nelfinavir treatment in the SARS-CoV-2 infection model in rhesus macaques, one group of three rhesus macaques was administered 200 mg/kg nelfinavir three times by nasogastric administration before SARS-CoV-2 (strain 20SF107) inoculation (black circles). One group of three control animals was administered 5 mL/kg vehicle solution (0.5%CMC-Na) by nasogastric administration. Treatment was continued twice daily until 7 dpi, then all animals were euthanized on 8dpi. At 0, 1, 3, 5, and 7 dpi, nasal, throat, and rectal swabs were collected. Temperature and weight changes were monitored at 0, 1, 2, 3, 4, 5, 6, and 7 dpi. Blood samples were taken at 0, 1, 3, 5, and 7 dpi

Back to article page